Replies to post #173733 on Biotech Values

[jq1234]

Here is GILD 4Q2013 presentation slides:

http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjE4ODUxfENoaWxkSUQ9LTF8VHlwZT0z&t=1

The most notable is plan to file sofosbuvir/ledipadvir FDC in treatment naive and experienced GT1 patients for 8/12-week treatment regimen without ribavirin on page 10.